-
“I want to congratulate GervanoRA and the team for the fantastic "Skin Cancer" report created. In fact it has become a tool for all of us in Vidac Pharma and we have used the precious data included to create new business approaches. I particularly appreciated the analysis of failed clinical trials and analysis of further opportunities.”
Dr. Max HerzbergChairman & CEO of Vidac Pharma Ltd
Vidac Pharma Ltd
Israel
-
“Ahead Therapeutics is a biotech company working on the field of "antigen-specific immune tolerance". We appreciate very much the reports provided by GervanoRA with regard to different auto-immune indications. The accuracy of the reports are useful to analyze the field and help taking decisions. They respect the timeline agreed to provide the reports.”
Marti DalmasesCEO of AHEAD THERAPEUTICS S.L.
AHEAD THERAPEUTICS S.L.
Barcelona, Spain
-
“The "Country Insights – India" report is an extensive report that I have reviewed and which helped us much in strategic decision making. In short, Country Insight reports are in-depth and useful. I strongly recommend these if anyone has a plan to expand their business overseas.”
Ashok KadamFounder & Director of Luminar Pharmaceuticals
India
-
“The "Global Psoriasis Therapeutic Market" report is one of the most comprehensive reports I have read and is a must have for any Medical Science Liaison team, Medical Affairs team and Sales & Marketing team that needs to get themselves and their team ready to launch their own product in the psoriasis space.”
Martijn BFounder & Director of "from SCIENCE to PHARMA"
from SCIENCE to PHARMA Pty Ltd
Australia
-
“I reviewed Multiple Sclerosis Pipeline Analysis 2018 Report which was extremely comprehensive to assess competitive landscape. It covered almost all the aspects one who can expects from competitive pipeline analysis reports. Analysts and customer support at GervanoRA are very responsive and skill full. I strongly recommend GervanoRA’s Pipeline Analysis Reports.”
Thomas Backstrom BCEO at BTB Pharma
Sweden
-
“The GervanoRA Data Services market report for Type-1 Diabetes was truly comprehensive and rich with facts and forecasts. The analysts who put this together hit everything that we needed for assessing commercial opportunity from the existing treatment armamentarium to pipeline assets, to deals and deal comparable (and more). I would recommend this report to anyone considering opportunities in the T1DM space or any other report from GervanoRA, assuming that this report is representative of the quality of their work.”
Andrew ReaumePresident & CEO at Melior Pharmaceuticals, Inc
USA
-
"The Cannabinoids Drugs – Pipeline Analysis and Opportunity Assessments H2 2018 Report is an in-depth report, well researched and very informative. Analytics provided by GervanoRA Analysts are realistic and helped me a lot to identify the key players & Emerging companies in the competitive landscape. I strongly recommend GervanoRA's Pipeline Analysis reports"
Adam MillerManaging Director of BuddingTech
Australia
-
“The Stimulant Abuse Deterrents and Treatments report provided by GervanoRa is a very comprehensive report full of details on the addiction landscape, technological innovations in the field from the very early development stage to the closest to market products. It helps us a lot to identify the most relevant actors in the field for partnering deals.”
Revital RattenbachCEO at 4P-Pharma
France
-
“Having received the sample report "Cannabinoid Drugs – Pipeline analysis and opportunity assessments H2 2018" we look forward to receiving the full report, to review in detail the data and insights GervanoRA have developed in regards to regulatory dynamics, unmet needs and opportunities, established company profiles and broader insights and analysis into the cannabis industry.”
Anna FisherChief Communications Officer at Hikurangi
New Zealand
-
"The Deterrents - Opportunity Assessments, Epidemiology Forecast, Market Dynamics and Pipeline Analysis H1 2019 report provides a very nice, comprehensive review of abuse of both prescription and illicit drugs. The report also provides a comprehensive description of compounds under development both to treat various addictions and to prevent abuse of prescription medications with abuse potential. The report is useful for anyone who wants a broad based view of these markets as well as detail on the companies, compounds, studies, and deals that have been made in these fields."
David BakerPresident & CEO at Vallon Pharmaceuticals Inc.
Philadelphia
-
“It was pleasure hosting a one day workshop on “Healthcare Data Analytics: Underlying Foundations & Perspectives” in collaboration with GervanoRA at our BITS Pilani K K Birla Goa campus. A number of student participants have really appreciated the efforts of the resource persons in making them understand the growing field of Data Analytics in Health care sector.”
Dr. Sukanta Mondal and Dr. Raviprasad AduriAssistant Professors at BITS Pilani, K K Birla Goa Campus
Goa
INDIA
-
“Cypralis Ltd. is developing a new drug to treat and prevent acute kidney injury. In that context we required a comprehensive overview of current treatment modalities, new therapies in development, future trends, companies active in this field, as well as market data. The report by GervanoRA Acute Kidney Failure Pipeline Drugs: Opportunity Assessments, Market Dynamics and Pipeline Analysis H2 2019 Report meets all our requirements. It is comprehensive, contains the newest developments in the field and is excellent value for money. Moreover, we found the entire team of GervanoRA extremely efficient, professional and pleasant to interact with. Cypralis will certainly utilize GervanoRA again in future for market intelligence purposes, should the need arise.”
Dr. Hans FliriChairman and CEO at Cypralis Ltd.
Cambridge CB22 3AT
U.K
-
“WPD Pharmaceuticals is focused on developing biological and chemical molecules involved in targeted therapy mostly for brain glioma and other central nervous system cancers. We have worked together with GervanoRa for the past 2 years. During that time, we ordered several customized opportunity assessment reports covering our pipeline products. Recently we obtained also valuable „COVID-19 Market Opportunity Assessments and Pipeline Analytics Report". All GervanoRa's reports were very comprehensive, prepared with great care and according to all quality standards. They covered exactly what we needed for indicated countries: disease overview, epidemiological and statistic data, current market value and forecast, comparative patent analytics, deals and collaboration analytics, r-NPV analysis etc. We are pleased to give our testimonials to GervanoRa and its team of highly qualified specialist. They always try to meet customers' needs and expectations and work according to indicated timelines.”
Mariusz OlejniczakCEO, WPD Pharmaceuticals
Poland